AI assistant
GlaxoSmithKline PLC — Remuneration Information 2016
Sep 26, 2016
5262_dirs_2016-09-26_97127577-fccd-48f7-8ada-291904ab073c.html
Remuneration Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 8628K
GlaxoSmithKline PLC
26 September 2016
GlaxoSmithKline plc (the 'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R G Connor
b)
Position/status
President, Global Manufacturing & Supply
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Following the vesting on 23 September 2016 of 50% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Mr R Connor will receive a cash payment of £237,076.13 less applicable tax withholding in respect of 14,376.963 notional Ordinary Shares.
c)
Price(s) and
volume(s)
| Price(s) | Volume(s) |
| £16.49 | 14,376.963 notional Ordinary Shares. |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2016-09-23
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr S A Hussain
b)
Position/status
President, Global Pharmaceuticals
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Following the vesting on 23 September 2016 of 50% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Mr Hussain will receive a cash payment of £296,345.16 less applicable tax withholding in respect of 17,971.204 notional Ordinary Shares.
c)
Price(s) and
volume(s)
| Price(s) | Volume(s) |
| £16.49 | 17,971.204 notional Ordinary Shares |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2016-09-23
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D S Redfern
b)
Position/status
Chief Strategy Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Following the vesting on 23 September 2016 of 50% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Mr Redfern will receive a cash payment of £237,076.13 less applicable tax withholding in respect of 14,376.963 notional Ordinary Shares.
c)
Price(s) and
volume(s)
| Price(s) | Volume(s) |
| £16.49 | 14,376.963 notional Ordinary Shares |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2016-09-23
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms C Thomas
b)
Position/status
SVP, Human Resources
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Following the vesting on 23 September 2016 of 50% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Ms Thomas will receive a cash payment of £237,076.13 less applicable tax withholding in respect of 14,376.963 notional Ordinary Shares.
c)
Price(s) and
volume(s)
| Price(s) | Volume(s) |
| £16.49 | 14,376.963 notional Ordinary Shares |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2016-09-23
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr P J T Vallance
b)
Position/status
President, Pharmaceuticals Research & Development
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Following the vesting on 23 September 2016 of 50% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Mr Vallance will receive a cash payment of £296,345.16 less applicable tax withholding in respect of 17,971.204 notional Ordinary Shares.
c)
Price(s) and
volume(s)
| Price(s) | Volume(s) |
| £16.49 | 17,971.204 notional Ordinary Shares |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2016-09-23
f)
Place of the transaction
n/a
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHEQLFLQKFEBBK
//<![CDATA[$.ajaxSetup({headers: {'__RequestVerificationToken':'Egim_l6XDWZW78EcOCebZDkvJqyVJ99t-3DkIfnS9ubf4T6Ylp1SpZx2ADLuqmue-5DDNxSE7TVsD_LW88n2HqEa-vPLgKbv9Eyfue8kNdE1:KvPrWV6rQAo2PSbzeq75wByzsx8DCgQpYg-GVzjFCtJS_N2o9bpzm7wFwJnMl_rhIIHAxVO9jzJJGHEPYutKyKGenUVk-CvPKMl94Ax2RlM1'}});//]]>